PATENT CLAIM ANALYSIS

Application Number: 16301826
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "254060"]

Abstract:
The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.

Claim (Index 28):
A method according to  claim 26  or  27 , wherein said cancer is selected from the group consisting of non-small cell lung cancer, papillary thyroid cancer, neuroblastoma, pancreatic cancer and colorectal cancer.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 98.0
- Lexical Diversity: 1.13636
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14623904', '16050516', '16051815', '14953969', '15172478']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7978826606046517
- 35 USC 102 Novelty (BERT): 0.5136997352695221
- Combined Prediction Score: 0.7694643680711387
- Mean Citation Score: 293.132042
- Max Citation Score: 305.8803
- Similarity Product: 229.75548223702307

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test